News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Catalent Pharma Solutions and UMN Pharma Announce Collaboration for Biosimilar Development and Production in Japan


12/13/2012 9:27:42 AM

SOMERSET, NJ & AKITA, Japan--(BUSINESS WIRE)--Catalent Pharma Solutions and UMN Pharma Inc. today announced the signing of an agreement to provide UMN Pharma a broad range of biosimilar cell lines using Catalent’s proprietary GPEx® technology. The development and manufacturing programs will benefit from the GPEx technology producing very stable and high yielding cell lines. Under the agreement, UMN Pharma and its subsidiary UNIGEN, which is a contract manufacturer, will produce a number of biosimilars using Catalent’s GPEx cell lines. UMN Pharma, separately, will build an alliance of pharmaceutical companies for product development including clinical trials, marketing and sales. UMN Pharma plans to begin multiple biosimilar projects with their alliance companies for the Asian market on an ongoing basis. “There are great synergies between UMN Pharma and Catalent in terms of technologies, business structure, speed and culture,” commented Masahiro Michishita, Executive Chairman of UMN Pharma. “Harnessing Catalent’s broad biologics development and cell construction expertise gives UMN Pharma a unique platform to grow our biosimilars business globally.”

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES